CONMED CORPORATION (CNMD) Current Ratio
- Current ratio · latest quarter: Value 1.48×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.48× | Current assets / current liabilities. $675.66M ÷ $455.40M ≈ 1.48× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 675.66M USD | Assets, Current |
| Current obligations | 455.40M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 239.77M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 360.18M USD | Inventory, Net |
| Payables | 101.02M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $675.66M | $455.40M | (m) | (m) | $239.77M | $360.18M | $101.02M | (m) | 1.48× |
| 2025-12-31 | $672.86M | $315.04M | (m) | (m) | $247.83M | $355.54M | $93.65M | (m) | 2.14× |
| 2025-09-30 | $662.16M | $314.70M | (m) | (m) | $224.94M | $364.36M | $107.09M | (m) | 2.10× |
| 2025-06-30 | $657.78M | $294.84M | (m) | (m) | $234.15M | $362.25M | $101.05M | (m) | 2.23× |
| 2025-03-31 | $639.00M | $283.15M | (m) | (m) | $221.14M | $354.68M | $95.73M | (m) | 2.26× |
| 2024-12-31 | $640.01M | $278.13M | (m) | (m) | $237.73M | $346.72M | $102.25M | (m) | 2.30× |
| 2024-09-30 | $641.00M | $282.31M | (m) | (m) | $231.23M | $342.55M | $104.57M | (m) | 2.27× |
| 2024-06-30 | $623.83M | $266.41M | (m) | (m) | $239.22M | $322.36M | $101.29M | (m) | 2.34× |
| 2024-03-31 | $635.72M | $291.40M | (m) | (m) | $241.46M | $322.30M | $101.64M | (m) | 2.18× |
| 2023-12-31 | $615.65M | $310.73M | (m) | (m) | $242.28M | $318.32M | $88.22M | (m) | 1.98× |
| 2023-09-30 | $625.65M | $376.32M | (m) | (m) | $230.20M | $325.82M | $81.87M | (m) | 1.66× |
| 2023-06-30 | $615.52M | $353.17M | (m) | (m) | $229.26M | $327.31M | $78.58M | (m) | 1.74× |
| 2023-03-31 | $610.09M | $320.69M | (m) | (m) | $213.18M | $335.37M | $76.68M | (m) | 1.90× |
| 2022-12-31 | $581.23M | $296.55M | (m) | (m) | $191.34M | $332.32M | $73.39M | (m) | 1.96× |
| 2022-09-30 | $574.24M | $208.58M | (m) | (m) | $197.29M | $304.81M | $74.23M | (m) | 2.75× |
| 2022-06-30 | $577.19M | $201.09M | (m) | (m) | $202.12M | $289.71M | $73.97M | (m) | 2.87× |
| 2022-03-31 | $488.30M | $187.60M | (m) | (m) | $183.25M | $253.73M | $67.46M | (m) | 2.60× |
| 2021-12-31 | $460.12M | $196.65M | (m) | (m) | $183.88M | $231.64M | $58.20M | (m) | 2.34× |
| 2021-09-30 | $443.40M | $183.19M | (m) | (m) | $165.43M | $228.57M | $46.60M | (m) | 2.42× |
| 2021-06-30 | $443.18M | $198.46M | (m) | (m) | $168.97M | $211.32M | $55.66M | (m) | 2.23× |
| 2021-03-31 | $424.37M | $182.16M | (m) | (m) | $163.95M | $205.80M | $55.78M | (m) | 2.33× |
| 2020-12-31 | $416.65M | $190.20M | (m) | (m) | $177.15M | $194.87M | $53.31M | (m) | 2.19× |
| 2020-09-30 | $404.23M | $179.04M | (m) | (m) | $166.59M | $182.67M | $57.20M | (m) | 2.26× |
| 2020-06-30 | $378.71M | $150.61M | (m) | (m) | $143.41M | $175.72M | $39.83M | (m) | 2.51× |
| 2020-03-31 | $393.17M | $160.00M | (m) | (m) | $166.50M | $174.54M | $57.38M | (m) | 2.46× |
| 2019-12-31 | $397.36M | $188.09M | (m) | (m) | $189.10M | $164.62M | $55.97M | (m) | 2.11× |
| 2019-09-30 | $399.02M | $160.66M | $30.07M | (m) | $173.28M | $173.92M | $45.85M | $13.48M | 2.48× |
| 2019-06-30 | $397.28M | $155.80M | $22.55M | (m) | $179.04M | $172.80M | $51.14M | $13.52M | 2.55× |
| 2019-03-31 | $390.71M | $151.27M | $23.41M | (m) | $172.19M | $171.09M | $54.49M | $14.38M | 2.58× |
| 2018-12-31 | $374.35M | $160.94M | $17.51M | (m) | $181.55M | $154.60M | $53.50M | (m) | 2.33× |
| 2018-09-30 | $363.46M | $164.89M | $29.69M | (m) | $161.00M | $153.62M | $48.23M | $18.05M | 2.20× |
| 2018-06-30 | $347.40M | $176.67M | $23.40M | (m) | $161.69M | $143.41M | $52.12M | $16.95M | 1.97× |
| 2018-03-31 | $342.38M | $159.30M | $21.13M | (m) | $157.81M | $145.79M | $49.97M | $15.79M | 2.15× |
| 2017-12-31 | $356.78M | $150.00M | $32.62M | (m) | $167.04M | $141.44M | $42.04M | $14.70M | 2.38× |
| 2017-09-30 | $356.68M | $139.32M | $44.03M | (m) | $146.74M | $149.54M | $50.26M | $13.54M | 2.56× |
| 2017-06-30 | $340.31M | $129.71M | $40.14M | (m) | $145.39M | $136.47M | $46.46M | $12.45M | 2.62× |
| 2017-03-31 | $333.50M | $125.44M | $34.66M | (m) | $139.85M | $140.08M | $46.86M | $11.30M | 2.66× |
| 2016-12-31 | $330.51M | $113.95M | $27.43M | (m) | $148.24M | $135.87M | $41.65M | $10.20M | 2.90× |
| 2016-09-30 | $369.38M | $112.86M | $26.95M | (m) | $133.19M | $188.53M | $36.70M | $10.14M | 3.27× |
| 2016-06-30 | $371.00M | $106.22M | $23.30M | (m) | $139.62M | $179.91M | $32.03M | $10.14M | 3.49× |
| 2016-03-31 | $367.93M | $103.16M | $19.89M | (m) | $134.41M | $185.11M | $29.03M | $10.09M | 3.57× |
| 2015-12-31 | $359.80M | $119.72M | $72.50M | (m) | $133.86M | $133.36M | $34.72M | $1.34M | 3.01× |
| 2015-09-30 | $383.69M | $111.66M | $65.33M | (m) | $124.70M | $161.56M | $31.59M | $1.28M | 3.44× |
| 2015-06-30 | $374.27M | $109.88M | $62.22M | (m) | $129.66M | $149.18M | $27.36M | $1.28M | 3.41× |
| 2015-03-31 | $374.07M | $113.48M | $65.73M | (m) | $128.95M | $144.20M | $27.83M | $1.23M | 3.30× |
| 2014-12-31 | $381.15M | $115.96M | $66.33M | (m) | $129.29M | $148.15M | $23.75M | $1.23M | 3.29× |
| 2014-09-30 | $385.37M | $121.75M | $64.61M | (m) | $123.33M | $162.10M | $31.06M | $1.19M | 3.17× |
| 2014-06-30 | $385.33M | $104.62M | $60.41M | (m) | $135.08M | $157.01M | $26.76M | $1.19M | 3.68× |
| 2014-03-31 | $367.80M | $101.11M | $56.32M | (m) | $129.83M | $152.17M | $26.71M | $1.14M | 3.64× |
| 2013-12-31 | $372.13M | $111.27M | $54.44M | (m) | $140.43M | $143.21M | $27.45M | $1.14M | 3.34× |
| 2013-09-30 | $363.92M | $100.88M | $49.83M | (m) | $130.59M | $151.00M | $27.24M | $1.09M | 3.61× |
| 2013-06-30 | $358.61M | $99.16M | $38.12M | (m) | $140.57M | $148.72M | $27.22M | $1.09M | 3.62× |
| 2013-03-31 | $354.00M | $97.17M | $32.36M | (m) | $135.60M | $156.87M | $25.05M | $1.05M | 3.64× |
| 2012-12-31 | $348.89M | $125.21M | $23.72M | (m) | $139.12M | $156.23M | $23.62M | $1.05M | 2.79× |
| 2012-09-30 | $344.68M | $125.54M | $19.82M | (m) | $132.87M | $165.33M | $31.94M | $1.01M | 2.75× |
| 2012-06-30 | $337.44M | $135.25M | $16.25M | (m) | $136.09M | $159.15M | $29.06M | $22.53M | 2.49× |
| 2012-03-31 | $351.28M | $165.84M | $19.45M | (m) | $142.35M | $163.39M | $27.09M | $54.22M | 2.12× |
| 2011-12-31 | $356.72M | $131.18M | $26.05M | (m) | $135.64M | $168.44M | $21.16M | $54.56M | 2.72× |
| 2011-09-30 | $370.11M | $232.60M | $39.88M | (m) | $130.88M | $174.79M | $20.76M | $166.38M | 1.59× |
| 2011-06-30 | $368.18M | $210.35M | $24.33M | (m) | $152.69M | $169.25M | $20.98M | $144.06M | 1.75× |
| 2010-12-31 | $350.19M | $179.87M | $12.42M | (m) | $145.35M | $172.80M | $21.69M | $110.43M | 1.95× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |